George Tachas, PhD, on Evaluating Antisense Oligonucleotides in Non-Ambulant Boys With DMD
The lead scientist at Percheron Therapeutics discussed a phase 2 blinded study of ATL1102 being conducted in the Europe and Australia.
George Tachas, PhD, on Studying Proteomics of Antisense Oligonucleotides in DMD
The lead scientist at Percheron Therapeutics discussed the design of the study assessing proteomics of ATL1102.
George Tachas, PhD, on Targeting Inflammation in DMD With Antisense Oligonucleotides
The lead scientist at Percheron Therapeutics discussed how ATL1102 could target inflammation as a secondary cause of muscle damage in DMD.